Clinical Trials

Accrual Status
Limit to SWOG Trials

1027 Results

    View
    Open
    Phase
    Accrual
    45%
    SWOG Clinical Trial Number
    S1703

    Randomized trial comparing overall survival of patients monitored with serum tumor marker directed disease monitoring (STMDDM) versus usual care in patients with metastatic hormone receptor positive breast cancer
    Research Committee(s)
    Cancer Care Delivery
    Breast Cancer
    Activated
    07-16-2018
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1702

    A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
    Status Notes
    This study is closed to accrual effective 9/30/19 at 11:59p.m. PDT.
    Research Committee(s)
    Myeloma
    Activated
    03-08-2018
    Closed
    09-30-2019
    Closed
    Phase
    Accrual
    64%
    SWOG Clinical Trial Number
    S1400K

    A PHASE II STUDY OF ABBV-399 (PROCESS II) IN PATIENTS WITH C-MET POSITIVE STAGE IV OR RECURRENT SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
    Status Notes
    Effective on 12/21/18, S1400K will be permanently closed to accrual.

    Effective on 10/18/18 at 1:00 pm PST, S1400K will be temporarily closed to accrual.

    Effective on 2/5/18 at 2:00 pm PST, S1400K will be activated.

    This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
    Research Committee(s)
    Lung Cancer
    Activated
    02-05-2018
    Closed
    12-21-2018
    Closed
    Phase
    Accrual
    5%
    SWOG Clinical Trial Number
    S1612

    A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia Age 60 or Older
    Status Notes
    This study is temporarily closed to accrual, effective 10/22/18.
    Research Committee(s)
    Leukemia
    Activated
    12-22-2017
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1619

    A Feasibility Trial of Neoadjuvant Cisplatin - Pemetrexed - Atezolizumab with Adjuvant Maintenance Atezolizumab in Resectable Malignant Pleural Mesothelioma
    Status Notes
    This study will permanently close to Step 1 accrual effective May 1, 2020 at 11:59 p.m. Pacific.
    Research Committee(s)
    Lung Cancer
    Activated
    11-03-2017
    Closed
    05-01-2020
    ClinicalTrials.gov Registry Number
    NCT03228537
    Closed
    Phase
    Accrual
    42%
    SWOG Clinical Trial Number
    S1613

    A Randomized Phase II Study of Pertuzumab and Trastuzumab (TP) compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification
    Status Notes
    Step 1 is permanently closed to accrual effective December 31, 2021.
    Step 2 is permanently closed to accrual effective March 31, 2022.
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    10-09-2017
    Closed
    12-31-2021
    Closed
    Phase
    Accrual
    51%
    SWOG Clinical Trial Number
    S1400F

    A PHASE II STUDY OF MEDI4736 AND TREMELIMUMAB AS THERAPY FOR CHECKPOINT INHIBITOR REFRACTORY SQUAMOUS PATIENTS
    Status Notes
    Effective March 24, 2020 at 12:00 pm PST, S1400F Cohort 2 (Primary Resistance Cohort) will be permanently closed to accrual. This now closes the entire S1400F study to accrual.

    Effective November 6, 2019 at 2:00 pm PST, S1400F Cohort 1 (Acquired Resistance Cohort) will be permanently closed to accrual and Cohort 2 (Primary Resistance Cohort) will reactivate and open to accrual.

    This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
    Research Committee(s)
    Lung Cancer
    Activated
    10-02-2017
    Closed
    03-24-2020
    ClinicalTrials.gov Registry Number
    NCT03373760
    Closed
    Phase
    Accrual
    67%
    SWOG Clinical Trial Number
    S1607

    A Phase II Study Of Combining Talimogene laherparepvec (T-VEC) And PD-1 Blockade With Pembrolizumab In Patients With Advanced Melanoma Who Have Progressed On Anti-PD1 Therapy
    Status Notes
    This study permanently closed to accrual on 11/1/20.
    Research Committee(s)
    Melanoma
    Activated
    10-02-2017
    Closed
    11-01-2020
    ClinicalTrials.gov Registry Number
    NCT02965716
    Open
    Phase
    Accrual
    38%
    SWOG Clinical Trial Number
    S1501

    Prospective Evaluation of Carvedilol vs No treatment in Prevention of Cardiac Dysfunction in Patients with Metastatic HER-2+ Breast Cancer.
    Status Notes
    Effective with the Status Notice distributed with the 2/1/24 SWOG broadcast, this study will be temporarily closed to accrual effective February 1, 2024 12PM PST.

    For questions you may email the study team at: S1501question@swog.org
    Research Committee(s)
    Cancer Survivorship
    Breast Cancer
    Activated
    09-15-2017
    ClinicalTrials.gov Registry Number
    NCT03418961
    Open
    Phase
    Accrual
    81%
    SWOG Clinical Trial Number
    S1608

    Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
    Status Notes
    Re-opened to accrual as of March 10, 2023
    Research Committee(s)
    Lymphoma
    Activated
    08-10-2017
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1616

    A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent
    Research Committee(s)
    Melanoma
    Activated
    07-17-2017
    ClinicalTrials.gov Registry Number
    NCT03033576
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1602

    A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer
    Status Notes
    There is a monthly call for coordinators who have questions about this study. Send an email to S1602question@swog.org to be added.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    02-07-2017
    Closed
    12-15-2020
    ClinicalTrials.gov Registry Number
    NCT03091660
    Closed
    Phase
    Accrual
    85%
    SWOG Clinical Trial Number
    S1400G

    A PHASE II STUDY OF TALAZOPARIB FOR PREVIOUSLY TREATED HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
    Status Notes
    Effective July 23, 2018, S1400G will be permanently closed to accrual.

    Effective 2:00 p.m. Pacific Time on June 20th, 2018, S1400G will be temporarily closed to accrual.

    Effective 2:00 p.m. Pacific Time on February 7, 2017, S1400G will be open for patient accrual.


    This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    Lung Cancer
    Activated
    02-07-2017
    Closed
    07-23-2018
    Closed
    Phase
    Accrual
    85%
    SWOG Clinical Trial Number
    S1605

    Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
    Status Notes
    NOTE: This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    Genitourinary Cancer
    Activated
    02-07-2017
    ClinicalTrials.gov Registry Number
    NCT02844816
    Open
    Phase
    Accrual
    98%
    SWOG Clinical Trial Number
    S1609

    DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
    Status Notes
    Permanently Closed to Accrual: 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53.

    Temporarily Closed to Accrual: 40, 46.

    For the PD-L1 amplified cohort, patients do NOT need to qualify under one of the applicable histologies listed in Section 18.1.

    Patients may now be registered directly to S1609 without having to be enrolled on EAY131 ("NCI-MATCH"). See Revision #3 for details.


    Research Committee(s)
    Early Therapeutics & Rare Cancers
    Breast Cancer
    Gastrointestinal Cancer
    Genitourinary Cancer
    Lung Cancer
    Melanoma
    Activated
    01-13-2017
    ClinicalTrials.gov Registry Number
    02834013
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1512

    A Phase II Study of PD-1 Blockade with Pembrolizumab In Patients with Locally Advanced and Metastatic Desmoplastic Melanoma (DM)
    Status Notes
    This study will permanently close to accrual, effective 6/4/21.
    Research Committee(s)
    Melanoma
    Activated
    10-20-2016
    ClinicalTrials.gov Registry Number
    NCT #02775851
    Closed
    Phase
    Accrual
    93%
    SWOG Clinical Trial Number
    S1415CD

    A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)
    Status Notes
    This study was permanently closed to accrual effective 4/15/20.
    Research Committee(s)
    Cancer Care Delivery
    Activated
    10-07-2016
    ClinicalTrials.gov Registry Number
    NCT02728596
    Closed
    Phase
    Accrual
    86%
    SWOG Clinical Trial Number
    S1513

    Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC- 737664) in Metastatic Pancreatic Cancer
    Status Notes
    Effective Immediately (12/13/2017) S1513 is permanently closed. Patients currently receiving ABT-888 (Veliparib) must discontinue the experimental treatment but may continue on FOLFIRI alone. Patients on both arms should continue study follow-up.
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    09-01-2016
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1507

    A Phase II Trial Of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies.
    Status Notes
    This study permanently closed to accrual on March 15, 2018.
    Research Committee(s)
    Lung Cancer
    Activated
    07-18-2016
    Closed
    03-15-2018
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1416

    Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer (TNBC) and/or BRCA Mutation-Associated Breast Cancer, with or without Brain Metastases
    Status Notes
    S1416 will permanently close to accrual on 6/15/19.
    Research Committee(s)
    Breast Cancer
    Activated
    07-07-2016
    Closed
    06-15-2019